Uroxatral
NDC Package 0024-4200-10
Package Information
Uroxatral is alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0024-4200 and is authorized under FDA application NDA021287.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0024 - Sanofi-aventis U.s. Llc
- 0024-4200 - Uroxatral
- 0024-4200-10 - 1 BOTTLE in 1 CARTON / 100 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 0024-4200 - Uroxatral
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0024-4200-10 identifies a specific commercial package of 1 bottle in 1 carton / 100 tablet, extended release in 1 bottle of Uroxatral, labeled by Sanofi-aventis U.s. Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Sanofi-aventis U.s. Llc on June 05, 2009. The current certification is valid through September 30, 2015.
What are the primary indications for this medication?
Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night). Alfuzosin belongs to a class of drugs known as alpha blockers. Do not use this medication to treat high blood pressure.
How is this Sanofi-aventis U.s. Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00024420010. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.